CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Enveric Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Enveric Biosciences Inc
4851 Tamiami Trail N, Suite 200
Phone: (239) 302-1707p:239 302-1707 NAPLES, FL  34103  United States Ticker: ENVBENVB

Business Summary
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board MikeWebb 65 11/1/2022 6/13/2022
Chief Executive Officer, Director JosephTucker 55 9/16/2021 9/16/2021
Chief Financial Officer Kevin M.Coveney 59 3/13/2023 3/13/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MagicMed Industries, Inc. 3655 - 36 Street NW Calgary AB Canada
DC&M Partners, L.L.C. 2040 South Alma School Road Chandler AZ United States
Bellsoft, Inc. 3545 Cruse Road NW Lawrenceville GA United States

Business Names
Business Name
1306432 B.C. Unlimited Liability Company
Akos Biosciences, Inc.
Ameri100
10 additional Business Names available in full report.

General Information
Number of Employees: 7 (As of 12/31/2023)
Outstanding Shares: 7,294,005 (As of 3/21/2024)
Shareholders: 202
Stock Exchange: NASD
Federal Tax Id: 954484725
Fax Number: (732) 243-9254
Email Address: info@spatializer.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024